Pulse Biosciences Enrolls First Patients in Pivotal Atrial Fibrillation Trial
Pulse Biosciences (PLSE) has enrolled its first patients in a pivotal clinical trial for its nPulse Cardiac Catheter System to treat drug-resistant paroxysmal atrial fibrillation. The trial, NANOPULSE-AF, aims to enroll 215 patients across 30 centers in the U.S. and Europe, with results to be measured at 6 and 12 months post-procedure. The company received FDA approval for the study in December 2025.
Tickers: $PLSE
Topics: atrial fibrillation clinical trial FDA approval medical device Pulse Biosciences